New York – Canopy, the first Continuous Care Platform for oncology, today announced findings from two studies demonstrating the clinical impact of EHR-integrated Remote Therapeutic Monitoring for patients with various hematologic malignancies. These studies demonstrate the potential of the Canopy Platform to increase time on treatment and improve detection of high-risk toxicities in patients across a variety of therapies, including bispecific antibodies.
- Symptoms reported more quickly and frequently: Within 90 days of first treatment, patients using ePROs reported symptoms an average 38 days earlier than those using phone calls and also reported symptoms more frequently.
- Faster clinical responses: For symptoms needing clinical action, a median 47 minutes passed between ePROs submission and nurse triage assessment compared to a median 97.7 minutes for reports submitted by phone call.
- Increased time on treatment: Within90 days of first treatment, 76% of patients enrolled in ePROs and submitting a symptom report remained on treatment compared to 65% of patients not enrolled in ePROs.
“Our findings suggest that the Canopy Platform can significantly enhance both the speed and frequency of symptom detection in patients with lymphoid malignancies. By enabling earlier detection of critical symptoms, ePROs may help improve patient-provider communication and support more timely clinical response."
—James Essell, MD, lead author of the study, Medical Director of the Center for Cancer and Cellular Therapy at Oncology Hematology Care (OHC) and The Jewish Hospital, and Chair for Cellular Therapy at Sarah Cannon Research Institute
- Increased symptom communication: At 30 days post-treatment, 45% of patients actively monitored had communicated their symptoms from home, compared to 12.9% of those using phone-based reporting.
- Improved detection of high-risk toxicities: Patients monitored via Canopy had critical symptoms identified at higher frequencies than phone-based reporting: fatigue (55.6% vs 1.5%), pain (38.9% vs 9.2%), breathing difficulties (11% vs 3.1%), and fever (11% vs 9.2%).
“While showing significant clinical potential, novel therapeutics like bispecific antibodies have had limited adoption due to complex toxicity profiles that require vigilant monitoring. Our study demonstrates that Remote Therapeutic Monitoring may facilitate safer administration of emerging therapies in the community setting by detecting potential adverse events before they escalate to more critical issues."
—Benjamin Derman, MD, lead author of the study and Assistant Professor of Medicine at the University of Chicago Medicine
About Canopy
Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy’s Continuous Care Platform enables practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from high-quality care. Over the past year, Canopy has grown its provider base by 4X, now exceeding 1,200 providers across prominent practices nationwide.
Media Contact:
Kaitlin Hemric
kaitlin@canopycare.us
Learn More
Interested in learning more? Contact the Canopy team to schedule time to meet.